⌘K

Home/Filings/4/0001127602-21-007295

4//SEC Filing

Babu Yarlagadda S 4

Accession 0001127602-21-007295

CIK 0000882796other

View on SEC.gov Company Profile

Filed

Feb 22, 7:00 PM ET

Accepted

Feb 23, 4:25 PM ET

Size

8.0 KB

Accession

0001127602-21-007295

Insider Transaction Report

Form 4

Period: 2021-02-19

BIOCRYST PHARMACEUTICALS INCBCRX

Babu Yarlagadda S

VP Drug Discovery

Transactions

Exercise/Conversion
Common Stock
2021-02-19$4.15/sh+50,000$207,500→ 205,587 total
Tax Payment
Common Stock
2021-02-19$11.53/sh−22,431$258,629→ 183,156 total
Exercise/Conversion
Stock Option (Right to Buy)
2021-02-19−50,000→ 0 total
Exercise: $4.15From: 2012-03-01Exp: 2021-03-01→ Common Stock (50,000 underlying)

Footnotes (1)

[F1]Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise.

Documents

1 file

4
form4.xmlPrimary
PRIMARY DOCUMENT

Issuer

BIOCRYST PHARMACEUTICALS INC

CIK 0000882796

Entity typeother

Related Parties

1

filerCIK 0001452635

Filing Metadata

Form type: 4
Filed: Feb 22, 7:00 PM ET
Accepted: Feb 23, 4:25 PM ET
Size: 8.0 KB

View on SEC.gov